HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of XP-Design Assay Salmonella Serotyping Solution designed for the rapid detection and precise characterization of Salmonella spp. in food and environmental samples.
Salmonella are gram-negative, rod-shaped bacilli that can cause diarrheal illness in humans. According to the U.S. Department of Agriculture (USDA), Salmonella is the most frequently reported cause of foodborne illness, with an estimated 1.4 million cases and more than 400 deaths annually in the United States.
Bio-Rad's assays use real-time polymerase chain reaction (PCR) technology to amplify and detect specific DNA sequences of target serotypes using fluorescent probes. Molecular serotyping of Salmonella allows for fast reaction and decision making during an outbreak event and can aid in the monitoring of specific serotypes throughout the food processing plant environment.
The XP-Design Assay Salmonella Serotyping Solution provides a flexible approach to identify Salmonella serotypes after initial screening. The ready-to-use solution contains oligonucleotides (primers and probes) that are specific to the target serotype ensuring high specificity and reduces the risk of cross-reaction, delivering reliable results.
"With XP-Design Salmonella Serotyping Assays, we are setting a new standard for rapid and accurate food safety testing," said Franck Edouard, Senior Marketing Director, Food Science Division, Bio-Rad Laboratories. "This launch underscores our commitment to providing advanced, reliable tools for detecting and identifying Salmonella, which are crucial for ensuring food safety and consumer confidence."
For more information on Bio-Rad’s XP-Design Salmonella Assays, please visit bio-rad.com/XPDesign
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.6 billion in revenues in 2024. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products, our expectations about our products, and our commitment to providing advanced, reliable tools for detecting and identifying Salmonella. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include reductions in government funding or capital spending of our customers, global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contacts:
Bio-Rad Laboratories, Inc.
Wendy Lauer
wendy_lauer@bio-rad.com
Zyme Communications
Francesca Wallace
+447506 424 870
Francesca.wallace@zymecommunications.com